WALLBOX
Wallbox N.V. (NYSE: WBX), a leading provider of electric vehicle (EV) charging and energy management solutions, has today announced two strategic hirings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005548/en/
Myriam Lhermurier Boublil, appointed Chief Communications and Public Affairs Officer for Wallbox (Photo: Business Wire)
The company strengthens its corporate structure through the creation of a new communications and public affairs team, which will be led by Myriam Lhermurier Boublil. As Chief Communications & Public Affairs Officer, Myriam will lead a growing team, already well established in Spain and the United States. The communications and public affairs team will enhance the company's global communication as it works to facilitate the adoption of electric vehicles and change the current approach to energy management, promoting Wallbox's role as a leader in the EV sector.
The company reinforces its commercial growth potential with the hiring of Javier Riaño, who joins Wallbox as its new Chief Marketing Officer. Javier will report to Masud Rabbani, the company's Chief Business Officer, and will lead the company's corporate marketing, branding and e-commerce strategy globally, helping to strengthen the brand, which is already present in 113 countries and enjoys a leadership position in its main markets, including Europe and the United States.
Enric Asunción, CEO and co-founder of Wallbox said: “We are very pleased that Myriam and Javier have joined the Wallbox team. With the creation of the new Communications and Public Affairs department led by Myriam, we will progress our strategy of positioning Wallbox as a leader in the development of technologies for charging electric vehicles on a global scale. Myriam also brings us her extensive experience in the innovation and technology sector, which is a great asset for us as we continue our mission to be a key player driving change in the way the world uses energy”.
Masud Rabbani, Wallbox's Chief Business Officer, said: “I am delighted to welcome Javier. His extensive experience in corporate marketing, e-commerce, brand management and CRM management positions, among other responsibilities, will help us continue to position Wallbox as a benchmark brand in our main markets, increasing the acceleration of our global growth and expansion. Through his leadership, we hope to be able to creatively and strategically convey our value proposition and our goal to play a key role in the transition to sustainable mobility.”
Myriam Lhermurier Boublil, who has over 25 years of experience in communications and public affairs, led teams in Europe, the Middle East and Asia during her career at Google, where she amassed experience in various leadership positions over 14 years. She also led PayPal's international communications department for more than 3 years, before moving to Barcelona in 2021 to join Domestika as Senior Vice President of Global Communications. Myriam has a degree in International Business with a master's degree in Communications from the Sorbonne University in Paris. She speaks French, English, Spanish and Hebrew.
Javier Riaño has more than 24 years of experience in marketing management positions, mainly in the consumer goods sector. In his previous role , Riaño acted as vice president of corporate marketing for Spain and director of beauty and grooming for southern Europe at Procter & Gamble. Previously, Javier Riaño has worked in different roles within the field of marketing, brand communication and e-commerce at Procter & Gamble on an international level, in cities such as Barcelona, Madrid, Rome and Geneva. Riaño has a degree in business administration and economics from Universidad Pontificia Comillas and in Law from Universidad Nacional de Educación a Distancia (UNED). Javier speaks Spanish, French, English and Italian.
About Wallbox
Wallbox is a global technology company, dedicated to changing the way the world uses energy. Wallbox creates advanced electric vehicle charging and energy management systems that redefine the relationship between users and the network. Wallbox goes beyond charging electric vehicles to give users the power to control their consumption, save money and live more sustainably. Wallbox offers a complete portfolio of charging and energy management solutions for residential, semi-public, and public use in more than 113 countries around the world. Founded in 2015 in Barcelona, where the company’s headquarters are located, Wallbox currently has more than 1,200 employees in its offices across Europe, Asia, and America. For more information, visit www.wallbox.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005548/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
